Main Article Content
Oral lichen planus (OLP) is a common inflammatory disease of unknown etiology. The immunopathogenesis is T-cell mediated autoimmune disease. Various treatments have been tried to treat OLP but complete cure is difficult to achieve. Pimecrolimus is a new calcineurin inhibitor which can inhibit T-cell and mast-cell activation. We presented three cases of OLP patients treated with pimecrolimus 1 % cream 2 times daily for 4 weeks. All of the lesions showed improvement with nearly complete remission. No side effects were observed during 6-12 months follow-up in all cases.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.